MacroGenics insider exercises 40K options at $2.60

MACROGENICS INC (MGNX) reported that Sr VP, Research & CSO Ezio Bonvini40,000 shares at $2.60 per share on 2026-08-17.

Rhea-AI Filing Summary

MACROGENICS INC (MGNX) reported that Sr VP, Research & CSO Ezio Bonvini40,000 shares at $2.60 per share on 2026-08-17. This option exercise converted into 40,000 shares of Common Stock in an exercise-and-hold transaction. Following the transaction, Bonvini directly holds 185,799 shares of Common Stock and 88,000 Employee Stock Options with an exercise price of $2.60 per share expiring on 2035-02-07. Footnotes indicate a staggered vesting schedule for the option grant.

Insider Trade Summary

40,000 shares exercised/converted

Exercise 2 txns

Insider Bonvini Ezio

Role Sr VP, Research & CSO

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy) F2	40,000	$2.60	$104K
Exercise	Common Stock F1	40,000	$2.60	$104K

Holdings After Transaction: Employee Stock Option (right to buy) — 88,000 contracts (Direct); Common Stock — 185,799 shares (Direct)

Footnotes (2)

1. F1. The transaction represents an exercise and hold of options.
2. F2. 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

Key Figures

Options Exercised: 40,000 shares Exercise Price: $2.60 per share Common Shares Owned After: 185,799 shares +3 more

6 metrics

Options Exercised 40,000 shares Employee Stock Option (right to buy) exercised on 2026-08-17

Exercise Price $2.60 per share Exercise price for 40,000 Employee Stock Options

Common Shares Owned After 185,799 shares Directly owned Common Stock following the 2026-08-17 transaction

Options Held After 88,000 options Employee Stock Options remaining after the reported exercise

Option Expiration Date 2035-02-07 Expiration date of the Employee Stock Option grant exercised in part

Transaction Date 2026-08-17 Date of option exercise and resulting share acquisition

Key Terms

Employee Stock Option (right to buy), derivative security, exercise and hold

3 terms

Employee Stock Option (right to buy) financial

"security_title: "Employee Stock Option (right to buy)""

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

exercise and hold financial

"footnote: "The transaction represents an exercise and hold of options.""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MGNX executive Ezio Bonvini report on this Form 4?

Ezio Bonvini reported exercising 40,000 Employee Stock Options at $2.60 per share, receiving 40,000 shares of MacroGenics Common Stock. The transaction is characterized as an exercise-and-hold, meaning the acquired shares were retained rather than sold.

How many MGNX common shares does Ezio Bonvini own after this transaction?

After the transaction, Ezio Bonvini directly owns 185,799 shares of MacroGenics Common Stock. This reflects the addition of 40,000 shares acquired through option exercise on 2026-08-17, with no same-day sale of those newly issued shares disclosed.

What options did Ezio Bonvini exercise in MacroGenics (MGNX) and at what price?

Bonvini exercised 40,000 Employee Stock Options in MacroGenics at an exercise price of $2.60 per share. These options relate to a grant where vesting is staggered over time, and the options carry an expiration date of 2035-02-07.

How many MacroGenics (MGNX) stock options does Ezio Bonvini hold after the exercise?

Following the reported exercise, Bonvini holds 88,000 Employee Stock Options with an exercise price of $2.60 per share. These options are scheduled to expire on 2035-02-07, and they continue to vest according to the grant’s specified vesting schedule.

Was the MGNX insider transaction a purchase or sale of shares?

The transaction was an option exercise and share acquisition, not an open-market sale. Bonvini exercised options to acquire 40,000 shares of Common Stock and held the resulting shares, with no reported sale on the same date in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 04:20 PM Accepted by SEC EDGAR 08/18/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bonvini Ezio

(Last) (First) (Middle)

9704 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr VP, Research & CSO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2026		M(1)		40,000	A	$2.6	185,799	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$2.6	08/17/2026		M			40,000	(2)	02/07/2035	Common Stock	40,000	$2.6	88,000	D

Explanation of Responses:

1. The transaction represents an exercise and hold of options.

2. 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

Remarks:

	/s/ Beth A. Smith, Attorney-in-fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)